SGLT2 Inhibitors and Complicated Urinary Tract Infections: A Rare Case of Emphysematous Pyelonephritis and Subsequent Recurrence Associated With Dapagliflozin Use
Abstract
Clinicians should exercise caution when prescribing dapagliflozin, a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor, as it may increase the risk of severe and complicated urinary tract infections (UTIs). This case illustrates how a patient with no prior UTI history developed emphysematous pyelonephritis, a severe life‐threatening renal infection, while on dapagliflozin. The patient subsequently developed recurrent pyelonephritis upon resuming the medication, further underscoring the potential association between dapagliflozin use and complicated UTIs.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.